Intricate Regulation of Phosphoenolpyruvate Carboxykinase (PEPCK) Isoforms in Normal Physiology and Disease

Author(s): Venu Seenappa, Manjunath B. Joshi, Kapaettu Satyamoorthy*.

Journal Name: Current Molecular Medicine

Volume 19 , Issue 4 , 2019

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer

Abstract:

Background: The phosphoenolpyruvate carboxykinase (PEPCK) isoforms are considered as rate-limiting enzymes for gluconeogenesis and glyceroneogenesis pathways. PEPCK exhibits several interesting features such as a) organelle-specific isoforms (cytosolic and a mitochondrial) in vertebrate clade, b) tissue-specific expression of isoforms and c) organism-specific requirement of ATP or GTP as a cofactor. In higher organisms, PEPCK isoforms are intricately regulated and activated through several physiological and pathological stimuli such as corticoids, hormones, nutrient starvation and hypoxia. Isoform-specific transcriptional/translational regulation and their interplay in maintaining glucose homeostasis remain to be fully understood. Mounting evidence indicates the significant involvement of PEPCK isoforms in physiological processes (development and longevity) and in the progression of a variety of diseases (metabolic disorders, cancer, Smith–Magenis syndrome).

Objective: The present systematic review aimed to assimilate existing knowledge of transcriptional and translational regulation of PEPCK isoforms derived from cell, animal and clinical models.

Conclusion: Based on current knowledge and extensive bioinformatics analysis, in this review we have provided a comparative (epi)genetic understanding of PCK1 and PCK2 genes encompassing regulatory elements, disease-associated polymorphisms, copy number variations, regulatory miRNAs and CpG densities. We have also discussed various exogenous and endogenous modulators of PEPCK isoforms and their signaling mechanisms. A comprehensive review of existing knowledge of PEPCK regulation and function may enable identification of the underlying gaps to design new pharmacological strategies and interventions for the diseases associated with gluconeogenesis.

Keywords: CpG Methylation, SNP, mutation, CNV, miRNA, tumor, hypoxia, AU elements.

[1]
Froy O. Metabolism and circadian rhythms--implications for obesity. Endocr Rev 2010; 31: 1-24.
[2]
Finkelstein J, Gray N, Heemels MT, Marte B, Nath D. Metabolism and disease. Nature 2012; 491: 347.
[3]
Eckel-Mahan K, Sassone-Corsi P. Metabolism and the circadian clock converge. Physiol Rev 2013; 93: 107-35.
[4]
Sprague JE, Arbelaez AM. Glucose counterregulatory responses to hypoglycemia. Pediatr Endocrinol Rev 2011; 9: 463-73.
[5]
Krebs H. The Croonian Lecture, 1963 Gluconeogenesis. Proc R Soc Lond B Biol Sci 1964; 159: 545-64.
[6]
Nelson DL, Cox MM. Lehninger principles of biochemistry. 4th ed. New York: Freeman 2005.
[7]
Xiong Y, Lei QY, Zhao S, Guan KL. Regulation of glycolysis and gluconeogenesis by acetylation of PKM and PEPCK. Cold Spring Harb Symp Quant Biol 2011; 76: 285-9.
[8]
Kalhan SC, Mahajan S, Burkett E, Reshef L, Hanson RW. Glyceroneogenesis and the source of glycerol for hepatic triacylglycerol synthesis in humans. J Biol Chem 2001; 276: 12928-31.
[9]
Kalhan SC, Bugianesi E, McCullough AJ, Hanson RW, Kelley DE. Estimates of hepatic glyceroneogenesis in type 2 diabetes mellitus in humans. Metabolism 2008; 57: 305-12.
[10]
Hanson RW. Thematic minireview series: a perspective on the biology of phosphoenolpyruvate carboxykinase 55 years after its discovery. J Biol Chem 2009; 284: 27021-3.
[11]
Hanson RW, Patel YM. Phosphoenolpyruvate carboxykinase (GTP): the gene and the enzyme. Adv Enzymol Relat Areas Mol Biol 1994; 69: 203-81.
[12]
Stark R, Kibbey RG. The mitochondrial isoform of phosphoenolpyruvate carboxykinase (PEPCK-M) and glucose homeostasis: has it been overlooked? Biochim Biophys Acta 2014; 840: 1313-30.
[13]
Diesterhaft M, Shrago E, Sallach HJ. Human liver phosphoenolpyruvate carboxykinase: evidence for a separate mitochondrial and cytosol enzyme. Biochem Med 1971; 5: 297-303.
[14]
Hanson RW, Garber AJ. Phosphoenolpyruvate carboxykinase I Its role in gluconeogenesis. Am J Clin Nutr 1972; 25: 1010-21.
[15]
Stoffel M, Xiang KS, Espinosa R III, Cox NJ, Le Beau MM, Bell GI. cDNA sequence and localization of polymorphic human cytosolic phosphoenolpyruvate carboxykinase gene (PCK1) to chromosome 20 band q1331: PCK1 is not tightly linked to maturity-onset diabetes of the young. Hum Mol Genet 1993; 2: 1-4.
[16]
Yu H, Thun R, Chandrasekharappa S, Trent JM, Zhang J, Meisler MH. Human PCK1 encoding phosphoenolpyruvate carboxykinase is located on chromosome 20q132. Genomics 1993; 15: 219-21.
[17]
Modaressi S, Christ B, Bratke J, Zahn S, Heise T, Jungermann K. Molecular cloning sequencing and expression of the cDNA of the mitochondrial form of phosphoenolpyruvate carboxykinase from human liver. Biochem J 1996; 315(3): 807-14.
[18]
Modaressi S, Brechtel K, Christ B, Jungermann K. Human mitochondrial phosphoenolpyruvate carboxykinase 2 gene Structure chromosomal localization and tissue-specific expression. Biochem J 1998; 333(2): 359-66.
[19]
Chakravarty K, Cassuto H, Reshef L, Hanson RW. Factors that control the tissue-specific transcription of the gene for phosphoenolpyruvate carboxykinase-C. Crit Rev Biochem Mol Biol 2005; 40: 129-54.
[20]
Liu JS, Park EA, Gurney AL, Roesler WJ, Hanson RW. Cyclic AMP induction of phosphoenolpyruvate carboxykinase (GTP) gene transcription is mediated by multiple promoter elements. J Biol Chem 1991; 266: 19095-102.
[21]
Roesler WJ, Vandenbark GR, Hanson RW. Identification of multiple protein binding domains in the promoter-regulatory region of the phosphoenolpyruvate carboxykinase (GTP) gene. J Biol Chem 1989; 264: 9657-64.
[22]
Allen-Jennings AE, Hartman MG, Kociba GJ, Hai T. The roles of ATF3 in liver dysfunction and the regulation of phosphoenolpyruvate carboxykinase gene expression. J Biol Chem 2002; 277: 20020-5.
[23]
Cheong J, Coligan JE, Shuman JD. Activating transcription factor-2 regulates phosphoenolpyruvate carboxykinase transcription through a stress-inducible mitogen-activated protein kinase pathway. J Biol Chem 1998; 273: 22714-8.
[24]
Gurney AL, Park EA, Giralt M, Liu J, Hanson RW. Opposing actions of Fos and Jun on transcription of the phosphoenolpyruvate carboxykinase (GTP) gene Dominant negative regulation by Fos. J Biol Chem 1992; 267: 18133-9.
[25]
Imai E, Stromstedt PE, Quinn PG, Carlstedt-Duke J, Gustafsson JA, Granner DK. Characterization of a complex glucocorticoid response unit in the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol 1990; 10: 4712-9.
[26]
Hall RK, Sladek FM, Granner DK. The orphan receptors COUP-TF and HNF-4 serve as accessory factors required for induction of phosphoenolpyruvate carboxykinase gene transcription by glucocorticoids. Proc Natl Acad Sci USA 1995; 92: 412-6.
[27]
O’Brien RM, Lucas PC, Forest CD, Magnuson MA, Granner DK. Identification of a sequence in the PEPCK gene that mediates a negative effect of insulin on transcription. Science 1990; 249: 533-7.
[28]
Puigserver P, Rhee J, Donovan J, et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 2003; 423: 550-5.
[29]
Azzout-Marniche D, Becard D, Guichard C, Foretz M, Ferre P, Foufelle F. Insulin effects on sterol regulatory-element-binding protein-1c (SREBP-1c) transcriptional activity in rat hepatocytes. Biochem J 2000; 350(2): 389-93.
[30]
Chakravarty K, Wu SY, Chiang CM, Samols D, Hanson RW. SREBP-1c and Sp1 interact to regulate transcription of the gene for phosphoenolpyruvate carboxykinase (GTP) in the liver. J Biol Chem 2004; 279: 15385-95.
[31]
Wan Z, Matravadia S, Holloway GP, Wright DC. FAT/CD36 regulates PEPCK expression in adipose tissue. Am J Physiol Cell Physiol 2013; 304(5): C478-84.
[32]
Mendez-Lucas A, Hyrossova P, Novellasdemunt L, Vinals F, Perales JC. Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) is a pro-survival endoplasmic reticulum (ER) stress response gene involved in tumor cell adaptation to nutrient availability. J Biol Chem 2014; 289: 22090-102.
[33]
Seenappa V, Das B, Joshi MB, Satyamoorthy K. Context Dependent Regulation of Human Phosphoenolpyruvate Carboxykinase Isoforms by DNA Promoter Methylation and RNA Stability. J Cell Biochem 2016; 117: 2506-20.
[34]
Gonzaga-Jauregui C, Lupski JR, Gibbs RA. Human genome sequencing in health and disease. Annu Rev Med 2012; 63: 35-61.
[35]
Rebbeck TR, Spitz M, Wu X. Assessing the function of genetic variants in candidate gene association studies. Nat Rev Genet 2004; 5: 589-97.
[36]
Lenhard B, Sandelin A, Carninci P. Metazoan promoters: emerging characteristics and insights into transcriptional regulation. Nat Rev Genet 2012; 13: 233-45.
[37]
Beale EG, Harvey BJ, Forest C. PCK1 and PCK2 as candidate diabetes and obesity genes. Cell Biochem Biophys 2007; 48: 89-95.
[38]
Cao H, van der Veer E, Ban MR, et al. Promoter polymorphism in PCK1 (phosphoenolpyruvate carboxykinase gene) associated with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004; 89: 898-903.
[39]
Rees SD, Britten AC, Bellary S, et al. The promoter polymorphism -232C/G of the PCK1 gene is associated with type 2 diabetes in a UK-resident South Asian population. BMC Med Genet 2009; 10: 83.
[40]
Duplus E, Benelli C, Reis AF, Fouque F, Velho G, Forest C. Expression of phosphoenolpyruvate carboxykinase gene in human adipose tissue: induction by rosiglitazone and genetic analyses of the adipocyte-specific region of the promoter in type 2 diabetes. Biochimie 2003; 85: 1257-64.
[41]
Ioannidis JP, Kavvoura FK. Concordance of functional in vitro data and epidemiological associations in complex disease genetics. Genet Med 2006; 8: 583-93.
[42]
Horikawa Y, Yamasaki T, Nakajima H, et al. Identification of a novel variant in the phosphoenolpyruvate carboxykinase gene promoter in Japanese patients with type 2 diabetes. Horm Metab Res 2003; 35: 308-12.
[43]
Shin HD, Park BL, Kim LH, et al. Association of a polymorphism in the gene encoding phosphoenolpyruvate carboxykinase 1 with high-density lipoprotein and triglyceride levels. Diabetologia 2005; 48: 2025-32.
[44]
Adams DR, Yuan H, Holyoak T, et al. Three rare diseases in one Sib pair: RAI1 PCK1 GRIN2B mutations associated with Smith-Magenis Syndrome cytosolic PEPCK deficiency and NMDA receptor glutamate insensitivity. Mol Genet Metab 2014; 113: 161-70.
[45]
Santra S, Cameron JM, Shyr C, et al. Cytosolic phosphoenolpyruvate carboxykinase deficiency presenting with acute liver failure following gastroenteritis. Mol Genet Metab 2016; 118: 21-7.
[46]
Vieira P, Cameron J, Rahikkala E, Keski-Filppula R, Zhang LH, Santra S, et al. Novel homozygous PCK1 mutation causing cytosolic phosphoenolpyruvate carboxykinase deficiency presenting as childhood hypoglycemia, an abnormal pattern of urine metabolites and liver dysfunction. Mol Genet Metab 2017; 120(4): 337-41.
[47]
Shaw G, Kamen R. A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 1986; 46: 659-67.
[48]
Matoulkova E, Michalova E, Vojtesek B, Hrstka R. The role of the 3′ untranslated region in post-transcriptional regulation of protein expression in mammalian cells. RNA Biol 2012; 9: 563-76.
[49]
Chen CY, Ezzeddine N, Shyu AB. Messenger RNA half-life measurements in mammalian cells. Methods Enzymol 2008; 448: 335-57.
[50]
Hajarnis S, Schroeder JM, Curthoys NP. 3′-Untranslated region of phosphoenolpyruvate carboxykinase mRNA contains multiple instability elements that bind AUF1. J Biol Chem 2005; 280: 28272-80.
[51]
Cooper GM, Nickerson DA, Eichler EE. Mutational and selective effects on copy-number variants in the human genome. Nat Genet 2007; 39: S22-9.
[52]
Ionita-Laza I, Rogers AJ, Lange C, Raby BA, Lee C. Genetic association analysis of copy-number variation (CNV) in human disease pathogenesis. Genomics 2009; 93: 22-6.
[53]
Zhang F, Gu W, Hurles ME, Lupski JR. Copy number variation in human health disease and evolution. Annu Rev Genomics Hum Genet 2009; 10: 451-81.
[54]
Pang AW, MacDonald JR, Pinto D, et al. Towards a comprehensive structural variation map of an individual human genome. Genome Biol 2010; 11: R52.
[55]
Kim JI, Ju YS, Park H, et al. A highly annotated whole-genome sequence of a Korean individual. Nature 2009; 460: 1011-5.
[56]
Holliday R. The inheritance of epigenetic defects. Science 1987; 238: 163-70.
[57]
Holliday R. Epigenetics: a historical overview. Epigenetics 2006; 1: 76-80.
[58]
Benvenisty N, Mencher D, Meyuhas O, Razin A, Reshef L. Sequential changes in DNA methylation patterns of the rat phosphoenolpyruvate carboxykinase gene during development. Proc Natl Acad Sci USA 1985; 82: 267-71.
[59]
Nijland MJ, Mitsuya K, Li C, et al. Epigenetic modification of fetal baboon hepatic phosphoenolpyruvate carboxykinase following exposure to moderately reduced nutrient availability. J Physiol 2010; 588: 1349-59.
[60]
Jiang W, Wang S, Xiao M, et al. Acetylation regulates gluconeogenesis by promoting PEPCK1 degradation via recruiting the UBR5 ubiquitin ligase. Mol Cell 2011; 43: 33-44.
[61]
Hoile SP, Lillycrop KA, Thomas NA, Hanson MA, Burdge GC. Dietary protein restriction during F0 pregnancy in rats induces transgenerational changes in the hepatic transcriptome in female offspring. PLoS One 2011; 6: e21668.
[62]
Mihaylova MM, Vasquez DS, Ravnskjaer K, et al. Class IIa histone deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis. Cell 2011; 145: 607-21.
[63]
Crunkhorn S. Metabolic disease: New role for HDACs in glucose homeostasis. Nat Rev Drug Discov 2011; 10: 492.
[64]
Zhang J, Henagan TM, Gao Z, Ye J. Inhibition of glyceroneogenesis by histone deacetylase 3 contributes to lipodystrophy in mice with adipose tissue inflammation. Endocrinology 2011; 152: 1829-38.
[65]
Hatziapostolou M, Polytarchou C, Iliopoulos D. miRNAs link metabolic reprogramming to oncogenesis. Trends Endocrinol Metab 2013; 24: 361-73.
[66]
Pandey AK, Verma G, Vig S, Srivastava S, Srivastava AK, Datta M. miR-29a levels are elevated in the db/db mice liver and its overexpression leads to attenuation of insulin action on PEPCK gene expression in HepG2 cells. Mol Cell Endocrinol 2011; 332: 125-33.
[67]
Trakooljul N, Hicks JA, Liu HC. Identification of target genes and pathways associated with chicken microRNA miR-143. Anim Genet 2010; 41: 357-64.
[68]
Krzywinski M, Schein J, Birol I, et al. Circos: an information aesthetic for comparative genomics. Genome Res 2009; 19: 1639-45.
[69]
Yang WM, Min KH, Park SW, Lee W. Data on the expression of PEPCK in HepG2 hepatocytes transfected with miR-195. Data Brief 2017; 15: 747-51.
[70]
Luo A, Yan H, Liang J, et al. MicroRNA-21 regulates hepatic glucose metabolism by targeting FOXO1. Gene 2017; 5(627): 194-201.
[71]
Aich S, Delbaere LT. Phylogenetic study of the evolution of PEP-carboxykinase. Evol Bioinform Online 2007; 3: 333-40.
[72]
Fukuda W, Fukui T, Atomi H, Imanaka T. First characterization of an archaeal GTP-dependent phosphoenolpyruvate carboxykinase from the hyperthermophilic archaeon Thermococcus kodakaraensis KOD1. J Bacteriol 2004; 186: 4620-7.
[73]
Watt WB, Hudson RR, Wang B, Wang E. A genetic polymorphism evolving in parallel in two cell compartments and in two clades. BMC Evol Biol 2013; 13: 9.
[74]
Brech W, Shrago E, Wilken D. Studies on pyruvate carboxylase in rat and human liver. Biochim Biophys Acta 1970; 201: 145-54.
[75]
Ballard FJ, Hanson RW, Kronfeld DS, Raggi F. Metabolic changes in liver associated with spontaneous ketosis and starvation in cows. J Nutr 1968; 95: 160-72.
[76]
Ballard FJ. Kinetic studies with cytosol and mitochondrial phosphoenolpyruvate carboxykinases. Biochem J 1970; 120: 809-14.
[77]
Belo PS, Romsos DR, Leveille GA. Influence of diet on glucose tolerance on the rate of glucose utilization and on gluconeogenic enzyme activities in the dog. J Nutr 1976; 106: 1465-74.
[78]
Garthoff L, Wolf G, Mehlman MA. Subcellular distribution of pyruvate carboxylase and phosphoenolpyruvate carboxykinase in dog liver and kidney. Proc Soc Exp Biol Med 1972; 141: 532-5.
[79]
Nordlie RC, Lardy HA. Mammalian liver phosphoneolpyruvate carboxykinase activities. J Biol Chem 1963; 238: 2259-63.
[80]
Soling HD, Kleineke J, Willms B, Janson G, Kuhn A. Relationship between intracellular distribution of phosphoenolpyruvate carboxykinase regulation of gluconeogenesis and energy cost of glucose formation. Eur J Biochem 1973; 37: 233-43.
[81]
Savon SP, Hakimi P, Crawford DR, Klemm DJ, Gurney AL, Hanson RW. The promoter regulatory regions of the genes for the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) from the chicken and the rat have different species-specific roles in gluconeogenesis. J Nutr 1997; 127: 276-85.
[82]
Watford M, Hod Y, Chiao YB, Utter MF, Hanson RW. The unique role of the kidney in gluconeogenesis in the chicken the significance of a cytosolic form of phosphoenolpyruvate carboxykinase. J Biol Chem 1981; 256: 10023-7.
[83]
Utter MF, Kurahashi K. Mechanism of action of oxalacetic carboxylase. J Biol Chem 1954; 207: 821-41.
[84]
Granner D, Andreone T, Sasaki K, Beale E. Inhibition of transcription of the phosphoenolpyruvate carboxykinase gene by insulin. Nature 1983; 305: 549-51.
[85]
Hanson RW, Reshef L. Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. Annu Rev Biochem 1997; 66: 581-611.
[86]
Hod Y, Hanson RW. Cyclic AMP stabilizes the mRNA for phosphoenolpyruvate carboxykinase (GTP) against degradation. J Biol Chem 1988; 263: 7747-52.
[87]
Lucas PC, Forman BM, Samuels HH, Granner DK. Specificity of a retinoic acid response element in the phosphoenolpyruvate carboxykinase gene promoter: consequences of both retinoic acid and thyroid hormone receptor binding. Mol Cell Biol 1991; 11: 5164-70.
[88]
Sutherland C, O’Brien RM, Granner DK. Phosphatidylinositol 3-kinase but not p70/p85 ribosomal S6 protein kinase is required for the regulation of phosphoenolpyruvate carboxykinase (PEPCK) gene expression by insulin Dissociation of signaling pathways for insulin and phorbol ester regulation of PEPCK gene expression. J Biol Chem 1995; 270: 15501-6.
[89]
Hall RK, Wang XL, George L, Koch SR, Granner DK. Insulin represses phosphoenolpyruvate carboxykinase gene transcription by causing the rapid disruption of an active transcription complex: a potential epigenetic effect. Mol Endocrinol 2007; 21: 550-63.
[90]
Li S, Brown MS, Goldstein JL. Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis but not inhibition of gluconeogenesis. Proc Natl Acad Sci USA 2010; 107: 3441-6.
[91]
Laplante M, Sabatini DM. mTORC1 activates SREBP-1c and uncouples lipogenesis from gluconeogenesis. Proc Natl Acad Sci USA 2010; 107: 3281-2.
[92]
Wu Z, Jiao P, Huang X, et al. MAPK phosphatase-3 promotes hepatic gluconeogenesis through dephosphorylation of forkhead box O1 in mice. J Clin Invest 2010; 120: 3901-11.
[93]
Xu H, Yang Q, Shen M, et al. Dual specificity MAPK phosphatase 3 activates PEPCK gene transcription and increases gluconeogenesis in rat hepatoma cells. J Biol Chem 2005; 280: 36013-8.
[94]
Michael MD, Kulkarni RN, Postic C, et al. Loss of insulin signaling in hepatocytes leads to severe insulin resistance and progressive hepatic dysfunction. Mol Cell 2000; 6: 87-97.
[95]
Zhou XY, Shibusawa N, Naik K, et al. Insulin regulation of hepatic gluconeogenesis through phosphorylation of CREB-binding protein. Nat Med 2004; 10: 633-7.
[96]
Yuan HD, Piao GC. An active part of Artemisia sacrorum Ledeb suppresses gluconeogenesis through AMPK mediated GSK3beta and CREB phosphorylation in human HepG2 cells. Biosci Biotechnol Biochem 2011; 75: 1079-84.
[97]
Yan J, Gao Z, Yu G, He Q, Weng J, Ye J. Nuclear corepressor is required for inhibition of phosphoenolpyruvate carboxykinase expression by tumor necrosis factor-alpha. Mol Endocrinol 2007; 21: 1630-41.
[98]
Yan JH, Gao ZG, Ye JP, Weng JP. Exchange of a nuclear corepressor between NF-kappaB and CREB mediates inhibition of phosphoenolpyruvate carboxykinase transcription by NF-kappaB. Chin Med J (Engl) 2010; 123: 221-6.
[99]
Pandey AK, Bhardwaj V, Datta M. Tumour necrosis factor-alpha attenuates insulin action on phosphoenolpyruvate carboxykinase gene expression and gluconeogenesis by altering the cellular localization of Foxa2 in HepG2 cells. FEBS J 2009; 276: 3757-69.
[100]
Hill MR, McCallum RE. Identification of tumor necrosis factor as a transcriptional regulator of the phosphoenolpyruvate carboxykinase gene following endotoxin treatment of mice. Infect Immun 1992; 60: 4040-50.
[101]
Wang JC, Stromstedt PE, Sugiyama T, Granner DK. The phosphoenolpyruvate carboxykinase gene glucocorticoid response unit: identification of the functional domains of accessory factors HNF3 beta (hepatic nuclear factor-3 beta) and HNF4 and the necessity of proper alignment of their cognate binding sites. Mol Endocrinol 1999; 13: 604-18.
[102]
Wang JC, Stafford JM, Scott DK, Sutherland C, Granner DK. The molecular physiology of hepatic nuclear factor 3 in the regulation of gluconeogenesis. J Biol Chem 2000; 275: 14717-21.
[103]
Waltner-Law M, Duong DT, Daniels MC, et al. Elements of the glucocorticoid and retinoic acid response units are involved in cAMP-mediated expression of the PEPCK gene. J Biol Chem 2003; 278: 10427-35.
[104]
Yamada K, Ogata-Kawata H, Matsuura K, Miyamoto K. SHARP-2/Stra13/DEC1 as a potential repressor of phosphoenolpyruvate carboxykinase gene expression. FEBS Lett 2005; 579: 1509-14.
[105]
Gabbay RA, Sutherland C, Gnudi L, et al. Insulin regulation of phosphoenolpyruvate carboxykinase gene expression does not require activation of the Ras/mitogen-activated protein kinase signaling pathway. J Biol Chem 1996; 271: 1890-7.
[106]
Wadzinski BE, Wheat WH, Jaspers S, et al. Nuclear protein phosphatase 2A dephosphorylates protein kinase A-phosphorylated CREB and regulates CREB transcriptional stimulation. Mol Cell Biol 1993; 13: 2822-34.
[107]
O’Brien RM, Noisin EL, Granner DK. Comparison of the effects of insulin and okadaic acid on phosphoenolpyruvate carboxykinase gene expression. Biochem J 1994; 303(3): 737-42.
[108]
Nin V, Chini CC, Escande C, Capellini V, Chini EN. Deleted in breast cancer 1 (DBC1) protein regulates hepatic gluconeogenesis. J Biol Chem 2014; 289: 5518-27.
[109]
Zhou D, Wang H, Cui H, Chen H, Pan YX. Early-life exposure to high-fat diet may predispose rats to gender-specific hepatic fat accumulation by programming Pepck expression. J Nutr Biochem 2015; 26: 433-40.
[110]
Strakovsky RS, Zhang X, Zhou D, Pan YX. Gestational high fat diet programs hepatic phosphoenolpyruvate carboxykinase gene expression and histone modification in neonatal offspring rats. J Physiol 2011; 589: 2707-17.
[111]
Wang J, Zhu X, Chen C, et al. Effect of insulin-like growth factor-1 (IGF-1) on the gluconeogenesis in calf hepatocytes cultured in vitro. Mol Cell Biochem 2012; 362: 87-91.
[112]
Potthoff MJ, Boney-Montoya J, Choi M, et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway. Cell Metab 2011; 13: 729-38.
[113]
Barthel A, Schmoll D, Kruger KD, et al. Differential regulation of endogenous glucose-6-phosphatase and phosphoenolpyruvate carboxykinase gene expression by the forkhead transcription factor FKHR in H4IIE-hepatoma cells. Biochem Biophys Res Commun 2001; 285: 897-902.
[114]
Kinote A, Faria JA, Roman EA, et al. Fructose-induced hypothalamic AMPK activation stimulates hepatic PEPCK and gluconeogenesis due to increased corticosterone levels. Endocrinology 2012; 153: 3633-45.
[115]
Yang J, Kong X, Martins-Santos ME, et al. Activation of SIRT1 by resveratrol represses transcription of the gene for the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) by deacetylating hepatic nuclear factor 4alpha. J Biol Chem 2009; 284: 27042-53.
[116]
Cowens KR, Simpson S, Thomas WK, Carey GB. Polybrominated Diphenyl Ether (PBDE)-Induced Suppression of Phosphoenolpyruvate Carboxykinase (PEPCK) Decreases Hepatic Glyceroneogenesis and Disrupts Hepatic Lipid Homeostasis. J Toxicol Environ Health A 2015; 78: 1437-49.
[117]
Nash JT, Szabo DT, Carey GB. Polybrominated diphenyl ethers alter hepatic phosphoenolpyruvate carboxykinase enzyme kinetics in male Wistar rats: implications for lipid and glucose metabolism. J Toxicol Environ Health A 2013; 76: 142-56.
[118]
White HM, Carvalho ER, Koser SL, et al. Short communication: Regulation of hepatic gluconeogenic enzymes by dietary glycerol in transition dairy cows. J Dairy Sci 2016; 99: 812-7.
[119]
Ribeiro LC, Chitto AL, Muller AP, et al. Ketogenic diet-fed rats have increased fat mass and phosphoenolpyruvate carboxykinase activity. Mol Nutr Food Res 2008; 52: 1365-71.
[120]
Yadav H, Jain S, Yadav M, Sinha PR, Prasad GB, Marotta F. Epigenomic derangement of hepatic glucose metabolism by feeding of high fructose diet and its prevention by Rosiglitazone in rats. Dig Liver Dis 2009; 41: 500-8.
[121]
Chen G. Liver lipid molecules induce PEPCK-C gene transcription and attenuate insulin action. Biochem Biophys Res Commun 2007; 361: 805-10.
[122]
Kabir M, Rizkalla SW, Quignard-Boulange A, et al. A high glycemic index starch diet affects lipid storage-related enzymes in normal and to a lesser extent in diabetic rats. J Nutr 1998; 128: 1878-83.
[123]
Botion LM, Kettelhut IC, Migliorini RH. Increased adipose tissue glyceroneogenesis in rats adapted to a high protein carbohydrate-free diet. Horm Metab Res 1995; 27: 310-3.
[124]
Caton PW, Nayuni NK, Murch O, Corder R. Endotoxin induced hyperlactatemia and hypoglycemia is linked to decreased mitochondrial phosphoenolpyruvate carboxykinase. Life Sci 2009; 84: 738-44.
[125]
Scribner KB, Odom DP, McGrane MM. Vitamin A status in mice affects the histone code of the phosphoenolpyruvate carboxykinase gene in liver. J Nutr 2005; 135: 2774-9.
[126]
Shin DJ, Tao A, McGrane MM. Effects of vitamin A deficiency and retinoic acid treatment on expression of a phosphoenolpyruvate carboxykinase-bovine growth hormone gene in transgenic mice. Biochem Biophys Res Commun 1995; 213: 706-14.
[127]
Shin DJ, McGrane MM. Vitamin A regulates genes involved in hepatic gluconeogenesis in mice: phosphoenolpyruvate carboxykinase fructose-16-bisphosphatase and 6-phosphofructo-2-kinase/fructose-26-bisphosphatase. J Nutr 1997; 127: 1274-8.
[128]
Titheradge MA, Picking RA, Haynes RC Jr. Physiological concentrations of 2-oxoglutarate regulate the activity of phosphoenolpyruvate carboxykinase in liver. Biochem J 1992; 285(3): 767-71.
[129]
Matsuoka H, Shima A, Kuramoto D, Kikumoto D, Matsui T, Michihara A. Phosphoenolpyruvate Carboxykinase a Key Enzyme That Controls Blood Glucose Is a Target of Retinoic Acid Receptor-Related Orphan Receptor alpha. PLoS One 2015; 10: e0137955.
[130]
Oda H, Okuda Y, Yoshida Y, Kimura N, Kakinuma A. Phenobarbital reduces blood glucose and gluconeogenesis through down-regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression in rats. Biochem Biophys Res Commun 2015; 466: 306-11.
[131]
Luo K, Chen P, Li S, Li W, He M, Wang T, et al. Effect of L-arginine supplementation on the hepatic phosphatidylinositol 3-kinase signaling pathway and gluconeogenic enzymes in early intrauterine growth-restricted rats. Exp Ther Med 2017; 14(3): 2355-60.
[132]
Si-Tayeb K, Lemaigre FP, Duncan SA. Organogenesis and development of the liver. Dev Cell 2010; 18: 175-89.
[133]
Collardeau-Frachon S, Scoazec JY. Vascular development and differentiation during human liver organogenesis. Anat Rec (Hoboken) 2008; 291: 614-27.
[134]
Yoder MC. Inducing definitive hematopoiesis in a dish. Nat Biotechnol 2014; 32: 539-41.
[135]
Mota-Rojas D, Orozco-Gregorio H, Villanueva-Garcia D, et al. Foetal and neonatal energy metabolism in pigs and humans: a review. Vet Med-Czech 2011; 56: 215-25.
[136]
Malone S, Chen ZH, Bahrami AR, Walker RP, Gray JE, Leegood RC. Phosphoenolpyruvate carboxykinase in Arabidopsis: changes in gene expression protein and activity during vegetative and reproductive development. Plant Cell Physiol 2007; 48: 441-50.
[137]
Kiefer JC. Epigenetics in development. Dev Dyn 2007; 236: 1144-56.
[138]
Cantone I, Fisher AG. Epigenetic programming and reprogramming during development. Nat Struct Mol Biol 2013; 20: 282-9.
[139]
Quinn PG, Yeagley D. Insulin regulation of PEPCK gene expression: a model for rapid and reversible modulation. Curr Drug Targets Immune Endocr Metabol Disord 2005; 5: 423-37.
[140]
Ballard FJ, Hanson RW. Phosphoenolpyruvate carboxykinase and pyruvate carboxylase in developing rat liver. Biochem J 1967; 104: 866-71.
[141]
Garcia Ruiz JP, Ingram R, Hanson RW. Changes in hepatic messenger RNA for phosphoenolpyruvate carboxykinase (GTP) during development. Proc Natl Acad Sci USA 1978; 75: 4189-93.
[142]
Mencher D, Shouval D, Reshef L. Premature appearance of hepatic phosphoenolpyruvate carboxykinase in fetal rats not mediated by adenosine 3′:5′-monophosphate. Eur J Biochem 1979; 102: 489-95.
[143]
Grun E, Pfuller K. Postnatal development of gluconeogenic key enzymes phosphoenolpyruvate carboxykinase and pyruvate carboxylase in pig liver. Acta Biol Med Ger 1982; 41: 515-23.
[144]
Caron RM, Hamilton JW. Developmentally specific effects of the DNA cross-linking agent mitomycin C on phosphoenolpyruvate carboxykinase gene expression in vivo: correlation with changes in chromatin structure within the promoter region of the gene. J Biochem Mol Toxicol 1998; 12: 325-37.
[145]
Hakimi P, Yang J, Casadesus G, et al. Overexpression of the cytosolic form of phosphoenolpyruvate carboxykinase (GTP) in skeletal muscle repatterns energy metabolism in the mouse. J Biol Chem 2007; 282: 32844-55.
[146]
Hammon HM, Sauter SN, Reist M, et al. Dexamethasone and colostrum feeding affect hepatic gluconeogenic enzymes differently in neonatal calves. J Anim Sci 2003; 81: 3095-106.
[147]
Hakimi P, Johnson MT, Yang J, et al. Phosphoenolpyruvate carboxykinase and the critical role of cataplerosis in the control of hepatic metabolism. Nutr Metab 2005; 2: 33.
[148]
She P, Shiota M, Shelton KD, Chalkley R, Postic C, Magnuson MA. Phosphoenolpyruvate carboxykinase is necessary for the integration of hepatic energy metabolism. Mol Cell Biol 2000; 20: 6508-17.
[149]
She P, Burgess SC, Shiota M, et al. Mechanisms by which liver-specific PEPCK knockout mice preserve euglycemia during starvation. Diabetes 2003; 52: 1649-54.
[150]
Burgess SC, He T, Yan Z, et al. Cytosolic phosphoenolpyruvate carboxykinase does not solely control the rate of hepatic gluconeogenesis in the intact mouse liver. Cell Metab 2007; 5: 313-20.
[151]
Sun Y, Liu S, Ferguson S, et al. Phosphoenolpyruvate carboxykinase overexpression selectively attenuates insulin signaling and hepatic insulin sensitivity in transgenic mice. J Biol Chem 2002; 277: 23301-7.
[152]
Mendez-Lucas A, Duarte JA, Sunny NE, et al. PEPCK-M expression in mouse liver potentiates not replaces PEPCK-C mediated gluconeogenesis. J Hepatol 2013; 59: 105-13.
[153]
Gomez-Valades AG, Mendez-Lucas A, Vidal-Alabro A, et al. Pck1 gene silencing in the liver improves glycemia control insulin sensitivity and dyslipidemia in db/db mice. Diabetes 2008; 57: 2199-210.
[154]
Montal ED, Dewi R, Bhalla K, et al. PEPCK Coordinates the Regulation of Central Carbon Metabolism to Promote Cancer Cell Growth. Mol Cell 2015; 60: 571-83.
[155]
Potts A, Uchida A, Deja S, Berglund ED, Kucejova B, Duarte JA, et al. Cytosolic phosphoenolpyruvate carboxykinase as a cataplerotic pathway in the small intestine. Am J Physiol Gastrointest Liver Physiol 2018; 315(2): G249-58.
[156]
Merritt ME, Harrison C, Sherry AD, Malloy CR, Burgess SC. Flux through hepatic pyruvate carboxylase and phosphoenolpyruvate carboxykinase detected by hyperpolarized 13C magnetic resonance. Proc Natl Acad Sci USA 2011; 108(47): 19084-9.
[157]
Hanson RW, Hakimi P. Born to run; the story of the PEPCK-Cmus mouse. Biochimie 2008; 90(6): 838-42.
[158]
Stark R, Guebre-Egziabher F, Zhao X, et al. A role for mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) in the regulation of hepatic gluconeogenesis. J Biol Chem 2014; 289: 7257-63.
[159]
Vincent EE, Sergushichev A, Griss T, et al. Mitochondrial Phosphoenolpyruvate Carboxykinase Regulates Metabolic Adaptation and Enables Glucose-Independent Tumor Growth. Mol Cell 2015; 60: 195-207.
[160]
Leithner K, Triebl A, Trotzmuller M, et al. The glycerol backbone of phospholipids derives from noncarbohydrate precursors in starved lung cancer cells. Proc Natl Acad Sci USA 2018; 115(24): 6225-30.
[161]
Hommes FA, Bendien K, Elema JD, Bremer HJ, Lombeck I. Two cases of phosphoenolpyruvate carboxykinase deficiency. Acta Paediatr Scand 1976; 65: 233-40.
[162]
Valera A, Pujol A, Pelegrin M, Bosch F. Transgenic mice overexpressing phosphoenolpyruvate carboxykinase develop non-insulin-dependent diabetes mellitus. Proc Natl Acad Sci USA 1994; 91: 9151-4.
[163]
Shao J, Qiao L, Janssen RC, Pagliassotti M, Friedman JE. Chronic hyperglycemia enhances PEPCK gene expression and hepatocellular glucose production via elevated liver activating protein/liver inhibitory protein ratio. Diabetes 2005; 54: 976-84.
[164]
Gastaldelli A, Toschi E, Pettiti M, et al. Effect of physiological hyperinsulinemia on gluconeogenesis in nondiabetic subjects and in type 2 diabetic patients. Diabetes 2001; 50: 1807-12.
[165]
Vidnes J, Sovik O. Gluconeogenesis in infancy and childhood III Deficiency of the extramitochondrial form of hepatic phosphoenolpyruvate carboxykinase in a case of persistent neonatal hypoglycaemia. Acta Paediatr Scand 1976; 65: 307-12.
[166]
Clayton PT, Hyland K, Brand M, Leonard JV. Mitochondrial phosphoenolpyruvate carboxykinase deficiency. Eur J Pediatr 1986; 145: 46-50.
[167]
Prandota J. Possible pathomechanisms of sudden infant death syndrome: key role of chronic hypoxia infection/inflammation states cytokine irregularities and metabolic trauma in genetically predisposed infants. Am J Ther 2004; 11: 517-46.
[168]
Xia Z, Chibnik LB, Glanz BI, et al. A putative Alzheimer’s disease risk allele in PCK1 influences brain atrophy in multiple sclerosis. PLoS One 2010; 5: e14169.
[169]
Hamilton G, Proitsi P, Jehu L, et al. Candidate gene association study of insulin signaling genes and Alzheimer’s disease: evidence for SOS2 PCK1 and PPARgamma as susceptibility loci. Am J Med Genet B Neuropsychiatr Genet 2007; 144B: 508-16.
[170]
Bose SK, Shrivastava S, Meyer K, Ray RB, Ray R. Hepatitis C virus activates the mTOR/S6K1 signaling pathway in inhibiting IRS-1 function for insulin resistance. J Virol 2012; 86: 6315-22.
[171]
Moreno-Sanchez R, Rodriguez-Enriquez S, Marin-Hernandez A, Saavedra E. Energy metabolism in tumor cells. FEBS J 2007; 274: 1393-418.
[172]
Leithner K, Hrzenjak A, Trotzmuller M, et al. PCK2 activation mediates an adaptive response to glucose depletion in lung cancer. Oncogene 2015; 34: 1044-50.
[173]
Noguchi Y, Yoshikawa T, Marat D, et al. Tumor-associated metabolic alterations in patients with gastric and esophageal cancer. Hepatogastroenterology 1999; 46: 555-60.
[174]
Zhang P, Tu B, Wang H, et al. Tumor suppressor p53 cooperates with SIRT6 to regulate gluconeogenesis by promoting FoxO1 nuclear exclusion. Proc Natl Acad Sci USA 2014; 111: 10684-9.
[175]
Motta MC, Divecha N, Lemieux M, et al. Mammalian SIRT1 represses forkhead transcription factors. Cell 2004; 116: 551-63.
[176]
Frescas D, Valenti L, Accili D. Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. J Biol Chem 2005; 280: 20589-95.
[177]
Wang B, Moya N, Niessen S, et al. A hormone-dependent module regulating energy balance. Cell 2011; 145: 596-606.
[178]
Goldstein I, Yizhak K, Madar S, Goldfinger N, Ruppin E, Rotter V. p53 promotes the expression of gluconeogenesis-related genes and enhances hepatic glucose production. Cancer Metab 2013; 1(1): 9.
[179]
Tang Y, Zhang Y, Wang C, et al. Overexpression of PCK1 Gene Antagonizes Hepatocellular Carcinoma Through the Activation of Gluconeogenesis and Suppression of Glycolysis Pathways. Cell Physiol Biochem 2018; 47(1): 344-55.
[180]
Liu MX, Jin L, Sun SJ, et al. Metabolic reprogramming by PCK1 promotes TCA cataplerosis, oxidative stress and apoptosis in liver cancer cells and suppresses hepatocellular carcinoma. Oncogene 2018; 37(12): 1637-53.
[181]
Chu PY, Jiang SS, Shan YS, et al. Mitochondrial phosphoenolpyruvate carboxykinase (PEPCK-M) regulates the cell metabolism of pancreatic neuroendocrine tumors (pNET) and de-sensitizes pNET to mTOR inhibitors. Oncotarget 2017; 8(61): 103613-25.
[182]
Ho PC, Bihuniak JD, Macintyre AN, et al. Phosphoenolpyruvate Is a Metabolic Checkpoint of Anti-tumor T Cell Responses. Cell 2015; 162: 1217-28.
[183]
Li Y, Zhang M, Dorfman RG, et al. SIRT2 Promotes the Migration and Invasion of Gastric Cancer through RAS/ERK/JNK/MMP-9 Pathway by Increasing PEPCK1-Related Metabolism. Neoplasia 2018; 20(7): 745-56.
[184]
Trapani S, Linss J, Goldenberg S, Fischer H, Craievich AF, Oliva G. Crystal structure of the dimeric phosphoenolpyruvate carboxykinase (PEPCK) from Trypanosoma cruzi at 2 A resolution. J Mol Biol 2001; 313: 1059-72.
[185]
Marrero J, Rhee KY, Schnappinger D, Pethe K, Ehrt S. Gluconeogenic carbon flow of tricarboxylic acid cycle intermediates is critical for Mycobacterium tuberculosis to establish and maintain infection. Proc Natl Acad Sci USA 2010; 107: 9819-24.
[186]
Tandon V, Das B. In vitro testing of anthelmintic efficacy of Flemingia vestita (Fabaceae) on carbohydrate metabolism in Rallietina echinobothrida. Methods 2007; 42: 330-8.
[187]
Sheikh TI, Adam T, Qadri I. Upregulated hepatic expression of mitochondrial PEPCK triggers initial gluconeogenic reactions in the HCV-3 patients. Asian Pac J Trop Med 2015; 8: 618-23.
[188]
Qadri I, Choudhury M, Rahman SM, et al. Increased phosphoenolpyruvate carboxykinase gene expression and steatosis during hepatitis C virus subgenome replication: role of nonstructural component 5A and CCAAT/enhancer-binding protein beta. J Biol Chem 2012; 287: 37340-51.
[189]
Chambers JW, Maguire TG, Alwine JC. Glutamine metabolism is essential for human cytomegalovirus infection. J Virol 2010; 84: 1867-73.
[190]
Brown JM, and Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58: 1408-16.
[191]
Denko NC. Hypoxia HIF1 and glucose metabolism in the solid tumour. Nat Rev Cancer 2008; 8: 705-13.
[192]
Bertout JA, Patel SA, Simon MC. The impact of O2 availability on human cancer. Nat Rev Cancer 2008; 8: 967-75.
[193]
Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 2010; 40: 294-309.
[194]
Ballard FJ. Regulation of gluconeogenesis during exposure of young rats to hypoxic conditions. Biochem J 1971; 121: 169-78.
[195]
Choi JH, Park MJ, Kim KW, et al. Molecular mechanism of hypoxia-mediated hepatic gluconeogenesis by transcriptional regulation. FEBS Lett 2005; 579: 2795-801.
[196]
Pison CM, Chauvin C, Fontaine E, et al. Mechanism of gluconeogenesis inhibition in rat hepatocytes isolated after in vivo hypoxia. Am J Physiol 1995; 268: E965-73.
[197]
Gu CJ, Yi HH, Feng J, et al. Intermittent Hypoxia Disrupts Glucose Homeostasis in Liver Cells in an Insulin-Dependent and Independent Manner. Cell Physiol Biochem 2018; 47(3): 1042-50.
[198]
Ye J. Emerging role of adipose tissue hypoxia in obesity and insulin resistance. Int J Obes (Lond) 2009; 33: 54-66.
[199]
Feingold KR, Moser A, Shigenaga JK, Grunfeld C. Inflammation inhibits the expression of phosphoenolpyruvate carboxykinase in liver and adipose tissue. Innate Immun 2012; 18: 231-40.
[200]
Sadasivam M, Ramatchandirin B, Balakrishnan S, Selvaraj K, Prahalathan C. The role of phosphoenolpyruvate carboxykinase in neuronal steroidogenesis under acute inflammation. Gene 2014; 552(2): 249-54.
[201]
Park EY, Lee CH, Lee EK, et al. HNF4alpha contributes to glucose formation in aged rat hepatocytes. Exp Gerontol 2013; 48: 1518-25.
[202]
Yuan Y, Hakimi P, Kao C, et al. Reciprocal Changes in Phosphoenolpyruvate Carboxykinase and Pyruvate Kinase with Age Are a Determinant of Aging in Caenorhabditis elegans. J Biol Chem 2016; 291: 1307-19.
[203]
Distefano JK, Watanabe RM. Pharmacogenetics of Anti-Diabetes Drugs. Pharmaceuticals (Basel) 2010; 3: 2610-46.
[204]
Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone metformin or glyburide monotherapy. N Engl J Med 2006; 355: 2427-43.
[205]
Hanhineva K, Torronen R, Bondia-Pons I, et al. Impact of dietary polyphenols on carbohydrate metabolism. Int J Mol Sci 2010; 11: 1365-402.
[206]
Jalil A, Ashfaq UA, Shahzadi S, et al. Screening and design of anti-diabetic compounds sourced from the leaves of neem (Azadirachta indica). Bioinformation 2013; 9: 1031-5.
[207]
Speciale A, Chirafisi J, Saija A, Cimino F. Nutritional antioxidants and adaptive cell responses: an update. Curr Mol Med 2011; 11: 770-89.
[208]
Das B, Tandon V, Saha N. Effects of phytochemicals of Flemingia vestita (Fabaceae) on glucose 6-phosphate dehydrogenase and enzymes of gluconeogenesis in a cestode (Raillietina echinobothrida). Comp Biochem Physiol C Toxicol Pharmacol 2004; 139: 141-6.
[209]
Choi MS, Jung UJ, Yeo J, Kim MJ, Lee MK. Genistein and daidzein prevent diabetes onset by elevating insulin level and altering hepatic gluconeogenic and lipogenic enzyme activities in non-obese diabetic (NOD) mice. Diabetes Metab Res Rev 2008; 24: 74-81.
[210]
Palanisamy N, Viswanathan P, Anuradha CV. Effect of genistein a soy isoflavone on whole body insulin sensitivity and renal damage induced by a high-fructose diet. Ren Fail 2008; 30: 645-54.
[211]
Ae Park S, Choi MS, Cho SY, et al. Genistein and daidzein modulate hepatic glucose and lipid regulating enzyme activities in C57BL/KsJ-db/db mice. Life Sci 2006; 79: 1207-13.
[212]
Dkhar B, Khongsti K, Thabah D, Syiem D, Satyamoorthy K, Das B. Genistein represses PEPCK-C expression in an insulin-independent manner in HepG2 cells and in alloxan-induced diabetic mice. J Cell Biochem 2018; 119(2): 1953-70.
[213]
Pletscher-Frankild S, Palleja A, Tsafou K, Binder JX, Jensen LJ. DISEASES: text mining and data integration of disease-gene associations. Methods 2015; 74: 83-9.


Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 19
ISSUE: 4
Year: 2019
Page: [247 - 272]
Pages: 26
DOI: 10.2174/1566524019666190404155801
Price: $65

Article Metrics

PDF: 35
HTML: 6

Special-new-year-discount